Director, Cardiovascular Epidemiology
CVI Program Unit(s):
Lipid / Atherobiology/ CAD / ACS / Prevention
CVI Research Description:
Dr. Kimmel's research is in cardiovascular epidemiology with a focus on drug epidemiology, pharmacogenomics, and adherence to medications.
Dr. Kimmel's research focuses on cardiac pharmacoepidemiology, with a particular interest in the effects and proper use of drugs and devices for patients with coronary artery disease. He is currently principal investigator on a number of grants evaluating cardiac medications, including a study examining the relationship between myocardial infarction and use of nonsteroidal anti-inflammatory drugs and a study examining the effects of genetic polymorphisms and patient adherence on anticoagulation control. He is also the principal investigator of a randomized trial designed to test economic and behavioral interventions to improve adherence with antihypertensive drugs. Dr. Kimmel has extensive experience performing studies examining complications from, and the proper use of, cardiovascular devices. He also is actively studying the influence of laboratory experience on outcomes.
Schelleman H, Berlin JA, Oslin DW, Weinstein RB, Kinman JL, Sauer WH, Lewis JD, Kimmel SE
: The Effect of Selective Serotonin Reuptake Inhibitors on The Risk of Myocardial Infarction in a Cohort of Patients With Depression. British Journal of Clinical Pharmacology 72: 514-517, 2011.
Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb
C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S: Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127(6): 1102-1110, 2011.
Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MTM, Pirmohamed M, Wadelius M, Klein TE, Altman RB: Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clinical Pharmacology and Therapeutics 90(4): 625-629, 2011.
Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S: Antidepressants and the risk of sudden cardiac death
and ventricular arrhythmia. Pharmacoepidemiology and Drug Safety 20: 903-13, 2011.
Flythe JE, Kimmel SE, Brunelli SM: Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 79: 250-257, 2011.
Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE: Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 57: 612-618, 2011.
Seminara NM, Abuabara K, Shin DB, Langan SM, Kimmel SE, Margolis D, Troxel AB, Gelfand JM: Validity of The Health Improvement Network (THIN) for the study of psoriasis. British Journal of Dermatology 164(3): 602-609, 2011.
Wade KC, Ellenberg JH, Grosser T, Brensinger CM, Kimmel SE, Hennessy S: Exogenous estrogen does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal women. Journal of Cardiovascular Pharmacology 57(2): 194-200, 2011.
Joo J, Geller N, French B, Kimmel S, Rosenberg Y, Ellenberg J: Prospectve Alpha Allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) Trial.
Clin Trials 7: 597-604, 2010.
Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE: New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 70: 393-399, 2010
back to top
Last updated: 10/07/2016
The Trustees of the University of Pennsylvania